Skip to Main text

Press Release 2016

2016/Nov/02

Building of the Innovative Platform for Vaccine Formulation

Initiation of Phase I Clinical Trial for Seasonal Influenza HA Vaccine Sublingual Tablet

Nitto Denko Corporation (Headquarters: Osaka; President, CEO&COO: Hideo Takasaki; “Nitto”, hereafter) initiated phase I clinical trials to sublingually administer a seasonal influenza HA vaccine tablet (code: NSV0001), a joint development with the Research Foundation for Microbial Diseases of Osaka University (Head Office: Suita city, Osaka; Director General: Koichi Yamanishi) on October 2016 in Japan.
Nitto’s tablet-type influenza vaccine is administered under the tongue and can induce specific antibodies on mucosal surfaces using an innovative platform containing a novel adjuvant. So this vaccine can not only deactivate infected viruses in human body, but also potentially prevent viruses themselves from infecting human body.
Nitto has been developing a tablet-type vaccination since 2009 in collaboration with Prof. Shizuo Akira of the WPI Immunology Frontier Center in Osaka University.
Nitto also aims for practical realization of this influenza vaccine as a first step and plans to expand this platform to other vaccines in the future.
Characteristics of the NSV0001 seasonal influenza vaccine tablet:
  • Potentially protect against infection and illness caused by the viruses
  • Painless administration (needle-free vaccination)
  • Possibly store at ambient temperature
Seasonal influenza HA vaccine: Commercialized influenza vaccine in Japan
Platform: Sublingual vaccine formulation containing the novel adjuvant
Adjuvant: Compound to enhance immune response
Under the slogan of “Innovation for Customers”, Nitto continues to create new value and businesses in the Green (Environment), Clean (New Energy) and Fine (Life Sciences) business domains in order to contribute to our customer’s value creation. Nitto aspires to establish an innovative platform and formulation for vaccination contributing to preventive care for people. This development is one of activities in Fine (Life Sciences) and Nitto makes efforts to deliver such innovative products to medical front as soon as possible.

BIKEN has been engaged in the development, production, and supply of a wide variety of important vaccines based on the results of pioneering basic research activities conducted by the Research Institute for Microbial Diseases in Osaka University for more than 80 years.
For further information, please visit http://www.biken.or.jp/english/

(For influenza HA vaccine)
Public Relations Section
Research Foundation for Microbial Diseases of Osaka University
TEL:+81-6-6877-4802
E MAIL:biken-pr@mail.biken.or.jp

Contact Us

For any inquiries about this press release.

Nitto Denko Singapore Pte. Ltd.
TEL:+65-6879-3811
FAX:+65-6274-7432
Notice
Here is the information at the release day. This information may be different from the information at other medias. Please be forewarned.

Back to Page Top